Zolmitriptan

Zolmitriptan is a selective serotonin-1b and serotonin-1d receptor agonist used for the acute treatment of migraine with or without aura. It belongs to the 'triptan' class of medications designed to narrow blood vessels around the brain and reduce inflammatory substances.

The standard starting dose for zolmitriptan oral tablets (both conventional and ODT) is 1.25 mg or 2.5 mg. Clinical trials have shown that the 2.5 mg dose provides a better balance of efficacy and safety for most patients. If the headache returns after an initial response, a second dose may be taken after at least 2 hours. However, the maximum dose in any 24-hour period must not exceed 10 mg. For the nasal spray, the typical dose is 2.5 mg or 5 mg administered into one nostril. Like the tablets, a second dose can be administered after 2 hours if the migraine persists or recurs, up to a 10 mg daily limit.

Zolmitriptan nasal spray is approved for use in pediatric patients aged 12 to 17 years. The recommended dose is 2.5 mg. The safety and effectiveness of the oral tablets in children under 18 have not been established, and they are generally not recommended for this population. Always consult a pediatrician before administering any triptan to a minor.

Renal Impairment

No dosage adjustment is typically required for patients with renal impairment, as the kidneys are not the primary site of metabolism, though they do handle excretion. However, patients with severe renal failure should be monitored for any unusual side effects.

Hepatic Impairment

For patients with mild to moderate hepatic (liver) impairment, no adjustment is usually necessary. However, in patients with severe hepatic impairment (e.g., Child-Pugh Grade C), the metabolism of zolmitriptan is significantly slowed. In these cases, a lower dose (e.g., 1.25 mg) is recommended, and the total daily dose should not exceed 5 mg. Use of the nasal spray is generally not recommended in patients with severe liver disease.

Elderly Patients

Clinical studies did not include sufficient numbers of patients over 65 to determine if they respond differently. However, because elderly patients are more likely to have underlying cardiovascular conditions (like heart disease or high blood pressure), zolmitriptan should be used with extreme caution and started at the lowest possible dose.

• Conventional Tablets: Swallow the tablet whole with water. It can be taken with or without food, though food may slightly delay the time it takes to reach peak levels.
• Orally Disintegrating Tablets (ODT): Do not open the blister pack until you are ready to take the dose. With dry hands, peel back the foil and place the tablet on your tongue. Allow it to dissolve and swallow with your saliva. No water is necessary.
• Nasal Spray: Blow your nose gently before use. Sit in an upright position. Remove the protective cap. Close one nostril by pressing your finger against it. Insert the tip of the sprayer into the other nostril (about half an inch). Breathe in gently through your nose while pressing the plunger. Keep your head level for a few seconds. Do not prime the nasal spray, as it is a single-dose device and you will lose the medication.
• Timing: For best results, take zolmitriptan as soon as the migraine headache begins. It is less effective if taken during the aura phase (before the pain starts).

Zolmitriptan is taken only as needed for an active migraine attack. It is not a daily medication. If you miss a dose during an attack, take it as soon as you remember, provided it has been at least 2 hours since your last dose and you have not exceeded the 10 mg daily limit.

There is no specific antidote for zolmitriptan. Signs of an overdose may include extreme drowsiness, severe dizziness, or significant increases in blood pressure. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Because zolmitriptan has a half-life of 3 hours, patients should be monitored for at least 15 hours or until symptoms resolve. Cardiovascular monitoring (ECG) is essential due to the risk of coronary vasospasm.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or take the medication more frequently than prescribed without medical guidance.

Most side effects of zolmitriptan are mild and transient, usually resolving within a few hours. The most frequently reported adverse reactions include:

• Paresthesia: A sensation of tingling, tickling, or 'pins and needles,' typically felt in the extremities, face, or scalp.
• Dizziness and Vertigo: A feeling of lightheadedness or as if the room is spinning, which may be exacerbated by moving too quickly.
• Somnolence: Significant drowsiness or tiredness. Patients should avoid driving until they know how the drug affects them.
• Nausea: While often a symptom of the migraine itself, some patients report increased queasiness after taking the medication.
• Triptan Sensations

Zolmitriptan is a potent vasoconstrictor (a substance that narrows blood vessels). While this is necessary to treat a migraine, it can pose risks to patients with underlying vascular conditions. It must only be used when a clear diagnosis of migraine has been made. If a patient does not respond to the first dose, the diagnosis should be reconsidered before a second dose is administered, as the symptoms may be related to a more serious condition like a stroke or brain hemorrhage.

There are no FDA black box warnings for Zolmitriptan as of 2026. However, the FDA requires strict adherence to the contraindications list, particularly regarding heart disease.

• Cardiovascular Risks: Zolmitriptan should not be given to patients with documented ischemic heart disease (IHD). For patients with multiple risk factors for IHD (e.g., hypertension, high cholesterol, smoking, obesity, diabetes, strong family history, or being postmenopausal or a male over 40), a cardiovascular evaluation should be performed before the first dose. If the evaluation is clear, the first dose should ideally be administered in a medically supervised setting with ECG monitoring.

• MAO-A Inhibitors: Monoamine oxidase inhibitors (such as phenelzine, tranylcypromine, or isocarboxazid) significantly increase the blood levels of zolmitriptan by blocking its primary metabolic pathway. Zolmitriptan is contraindicated in patients currently taking MAO-A inhibitors or those who have taken them within the last 14 days. This combination can lead to severe hypertension and serotonin toxicity.
• Ergotamine-Containing Medications: Drugs like ergotamine, dihydroergotamine (DHE), or methysergide also cause blood vessel constriction. Using them within 24 hours of zolmitriptan can cause additive and prolonged vasospastic reactions. You must wait at least 24 hours between using an ergot-type drug and zolmitriptan.
• Other Triptans: Using multiple triptans (e.g., sumatriptan, rizatriptan) within 24 hours is contraindicated due to the risk of excessive vasoconstriction.

Zolmitriptan must NEVER be used in the following circumstances because the risk of life-threatening complications outweighs any potential benefit:

• Ischemic Heart Disease (IHD): This includes patients with a history of myocardial infarction (heart attack), angina pectoris (chest pain), or documented silent ischemia. Zolmitriptan causes coronary artery constriction, which can trigger a heart attack in these patients.
• Coronary Artery Vasospasm: Including Prinzmetal’s variant angina. These patients have hyper-reactive blood vessels, and zolmitriptan can trigger severe, prolonged spasms.
• Wolff-Parkinson-White Syndrome: Or other arrhythmias associated with cardiac accessory conduction pathway disorders. Triptans have been associated with serious, sometimes fatal, heart rhythm disturbances in these patients.
• History of Stroke or TIA: Because zolmitriptan affects cerebral blood flow, it increases the risk of further cerebrovascular accidents.

Zolmitriptan is classified as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus (such as developmental delays and increased embryofetal lethality in rabbits), but there are no adequate and well-controlled studies in humans.

• Trimester-Specific Risks: During the first trimester, the primary concern is potential teratogenicity (birth defects), though data is limited. In the third trimester, the vasoconstrictive effects could theoretically affect uterine blood flow.
• Clinical Recommendation: Zolmitriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnant women are encouraged to participate in pregnancy registries to help track outcomes.

It is not known whether zolmitriptan is excreted in human breast milk. However, animal studies have shown that zolmitriptan is secreted into the milk of lactating rats, with concentrations up to four times higher than in the mother's plasma.

Zolmitriptan is a selective agonist for the 5-HT1B and 5-HT1D receptors. It has modest affinity for 5-HT1A receptors but negligible affinity for 5-HT2, 5-HT3, 5-HT4, alpha-adrenergic, beta-adrenergic, or dopaminergic receptors.

• 5-HT1B Binding: These receptors are located on the smooth muscle cells of intracranial blood vessels. Agonism here leads to vasoconstriction of the meningeal, dural, and cerebral arteries, which are pathologically dilated during a migraine.
• 5-HT1D Binding: These receptors are located on the sensory nerve endings of the trigeminal system. Agonism here inhibits the release of pro-inflammatory neuropeptides (CGRP, Substance P), which prevents neurogenic inflammation and stops the 'pain signal' from reaching the brain.

• Dose-Response: There is a clear dose-response relationship between 1 mg and 5 mg for headache response at 2 hours. However, doses higher than 5 mg provide little additional benefit but significantly increase side effects.